Discovery of Reversible Covalent Bruton’s Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib)
Timothy D. Owens, Ken A. Brameld, Erik Verner, Tony Ton, Xiaoyan Li, Jiang Zhu, Mohammad R. Masjedizadeh, J. Michael Bradshaw, Ronald J. Hill, Danny Tam, Angelina Bisconte, Eun Ok Kim, Michelle Francesco, Yan Xing, Jin Shu, Dane E. Karr, Jacob LaStant, David Finkle, Natalie Loewenstein, Helena Haberstock-Debic, Michael J. Taylor, Philip A. Nunn, Claire L. Langrish, David Goldstein
Abstract
Bruton’s tyrosine kinase (BTK), a Tec family tyrosine kinase, is critical in immune pathways as an essential intracellular signaling element, participating in both adaptive and immune responses. Currently approved BTK inhibitors are irreversible covalent inhibitors and limited to oncology indications. Herein, we describe the design of covalent reversible BTK inhibitors and the discoveries of PRN473 (11) and rilzabrutinib (PRN1008, 12). These compounds have exhibited potent and durable inhibition of BTK, in vivo efficacy in rodent arthritis models, and clinical efficacy in canine pemphigus foliaceus. Compound 11 has completed phase 1 trials as a topical agent, and 12 is in phase 3 trials for pemphigus vulgaris and immune thrombocytopenia.